pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 32 Non-oncology: 20
Oncology: 12
Under Consideration for Negotiation 23 Non-oncology: 17
Oncology: 6
Completed Negotiations 416 With Letter of Intent: 359
Without agreement: 57
Negotiations That Were Not Pursued 81

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Soliris Alexion Pharma GMBH Myasthenia Gravis
Tecentriq and bevacizumab HOFFMANN-LA ROCHE LIMITED Hepatocellular Carcinoma (HCC)

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Nyvepria Pfizer Canada Inc. febrile neutropenia in non-myeloid malignancies
Redesca Valeo Pharma Inc. Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
Xospata Astellas Pharma Inc. Acute Myeloid Leukemia

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Taltz Eli Lilly Canada Inc. Ankylosing spondylitis
Otezla Amgen Canada Inc. Psoriasis, moderate to severe plaque
Otezla Amgen Canada Inc. Psoriatic Arthritis

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks